Straits Times Index
3,305.21 -16.87 (-0.51%) Nikkei
39,134.79 +96.63 (+0.25%) Hang Seng
18,166.97 -199.98 (-1.09%) FTSE 100
8,251.50 +23.02 (+0.28%) Bitcoin USD
67,769.89 -1,656.01 (-2.39%) CMC Crypto 200
1,403.07 -38.57 (-2.68%)
Sedana Medical AB (publ) (7D2A.F)
| Previous close | 2.2900 |
| Open | 2.2900 |
| Bid | 2.2800 x N/A |
| Ask | 2.3350 x N/A |
| Day's range | 2.2900 - 2.2900 |
| 52-week range | 1.1620 - 2.8040 |
| Volume | |
| Avg. volume | 27 |
| Market cap | 229.838M |
| Beta (5Y monthly) | 0.26 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.0200 |
| Earnings date | 23 Jul 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
PR NewswireSedana Medical completes patient recruitment for its clinical program in the US
Sedana Medical AB (publ) announces that all 235 randomized patients have been recruited for its INSPiRE-ICU 2 phase III clinical trial in the United States. Earlier this spring, Sedana Medical reported the completion of enrolment to the parallel phase III clinical trial INSPiRE-ICU 1. The company anticipates topline results from both trials in the second half of 2024, with a planned New Drug Application (NDA) submission in the first quarter of 2025.
PR NewswireSedana Medical completes patient recruitment for INSPiRE-ICU 1 clinical trial in the US
Sedana Medical AB (publ) announces that all 235 randomized patients have been recruited for its INSPiRE-ICU 1 phase III clinical trial in the United States. Concurrently, the identical INSPiRE-ICU 2 trial is nearing completion, with 23 of 235 randomized patients remaining. The company anticipates topline results from both trials in the second half of 2024, with a planned New Drug Application (NDA) submission in the first quarter of 2025.
